Taher Abbasi

Learn More
Glioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH clinical collection (NCC) that includes 446 FDA-approved drugs, with the goal of identifying new GBM therapeutics for rapid entry into clinical trials(More)
BACKGROUND The increasing usage of statins (the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) has revealed a number of unexpected beneficial effects, including a reduction in cancer risk. METHODS We investigated the direct anticancer effects of different statins approved for clinical use on human breast and brain cancer cells. We also(More)
Introduction Ursolic acid (UA) is a pentacyclic triterpene acid present in many plants, including apples, basil, cranberries, and rosemary. UA suppresses proliferation and induces apoptosis in a variety of tumor cells via inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB). Given that single agent therapy is a major clinical(More)
Glioblastoma (GBM) is an aggressive disease associated with poor survival. It is essential to account for the complexity of GBM biology to improve diagnostic and therapeutic strategies. This complexity is best represented by the increasing amounts of profiling (“omics”) data available due to advances in biotechnology. The challenge of integrating these vast(More)
The personalization of cancer treatments implies the reconsideration of a one-size-fits-all paradigm. This move has spawned increased use of next generation sequencing to understand mutations and copy number aberrations in cancer cells. Initial personalization successes have been primarily driven by drugs targeting one patient-specific oncogene (e.g.,(More)
Glioblastoma multiforme (GBM) is an aggressive, malignant cancer Johnson and O'Neill (J Neurooncol 107: 359-364, 2012). An extract from the winter cherry plant (Withania somnifera ), AshwaMAX, is concentrated (4.3 %) for Withaferin A; a steroidal lactone that inhibits cancer cells Vanden Berghe et al. (Cancer Epidemiol Biomark Prev 23: 1985-1996, 2014). We(More)
Previous studies have shown that the bone marrow micro-environment supports the myeloproliferative neoplasms (MPN) phenotype including via the production of cytokines that can induce resistance to frontline MPN therapies. However, the mechanisms by which this occurs are poorly understood. Moreover, the ability to rapidly identify drug agents that can act as(More)
Correction After publishing this article [1], we noted mistake in the spelling of co-author Rajesh Mukthavaram's names. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Cite this article as: Jiang et al.: Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a(More)
Correction After publishing this article [1], we noted mistake in the spelling of co-author Rajesh Mukthavaram's names. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Cite this article as: Jiang et al.: Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a(More)
(Aug 07– Present) Advisor: Eric Rotenberg • FabScalar: Developed a novel approach to generate synthesizable RTL of an arbitrary out-of-order superscalar processor based on canonical pipeline template. Generated processors' RTL differ in the three major dimensions: superscalar width, pipeline depth, and sizes of structures for extracting instruction-level(More)